[1]
|
Institute of Medicine.Clinical practice guidelines we can trust[M].Washington (DC):National Academies Press, 2011. |
[2]
|
Djulbegovic B, Guyatt GH.Progress in evidence-based medicine:a quarter century on[J].Lancet, 2017, 390:415-423. doi: 10.1016/S0140-6736(16)31592-6 |
[3]
|
陈耀龙, 罗旭飞, 王吉耀, 等.如何区分临床实践指南与专家共识[J].协和医学杂志, 2019, 10:403-408. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201904018.htm |
[4]
|
陈耀龙, 马艳芳, 周奇, 等.谁应该参与临床实践指南的制订?[J].协和医学杂志, 2019, 10:524-530. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201905018.htm |
[5]
|
Chen Y, Yang K, Norris SL.Managing conflicts of interest in practice guidelines panels[J].JAMA, 2017, 318:866-867. |
[6]
|
Sox HC.Conflict of interest in practice guidelines panels[J].JAMA, 2017, 317:1739-1740. doi: 10.1001/jama.2017.2701 |
[7]
|
Schünemann HJ, Al-Ansary LA, Forland F, et al.Guidelines International Network:principles for disclosure of interests and management of conflicts in guidelines[J].Ann Intern Med, 2015, 163:548-553. doi: 10.7326/M14-1885 |
[8]
|
Norris SL, Holmer HK, Ogden LA, et al.Conflict of interest in clinical practice guideline development:a systematic review[J].PLoS One, 2011, 6:e25153. doi: 10.1371/journal.pone.0025153 |
[9]
|
Kanter GP, Loewenstein G.Evaluating open payments[J].JAMA, 2019.doi:10./001/jama.2019.8171.[Epub ahead of print]. |
[10]
|
Gao Y, Wang J, Luo X, et al.Quality appraisal of clinical practice guidelines for diabetes mellitus published in China between 2007 and 2017 using the AGREE Ⅱ instrument[J].BMJ Open, 2019, 9:e022392. doi: 10.1136/bmjopen-2018-022392 |
[11]
|
陈耀龙, 周奇, 崔荣荣, 等.基于AGREEⅡ的中医药临床指南质量评价[J].中国循证医学杂志, 2016, 16:1331-1337. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201611013.htm |
[12]
|
李楠, 姚亮, 吴琼芳, 等.2012-2013年中国大陆期刊发表临床实践指南质量评价[J].中国循证医学杂志, 2015, 15:259-263. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201503003.htm |
[13]
|
韦当, 王小琴, 吴琼芳, 等.2011年中国临床实践指南质量评价[J].中国循证医学杂志, 2013, 13:760-763. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201306028.htm |
[14]
|
Hu J, Chen R, Wu S, et al.The quality of clinical practice guidelines in China:a systematic assessment[J].J Eval Clin Pract, 2013, 19:961-967. |
[15]
|
Chen YL, Yao L, Xiao XJ, et al.Quality assessment of clinical guidelines in China:1993-2010[J].Chin Med J, 2012, 125:3660-3664. https://www.ncbi.nlm.nih.gov/pubmed/23075720 |
[16]
|
柯立鑫, 王津京, 王浩, 等.2016年中国大陆期刊发表临床实践指南的报告质量评价[J].中国循证儿科杂志, 2018:194-199. http://www.cnki.com.cn/Article/CJFDTotal-XZEK201803009.htm |
[17]
|
令娟, 王明霞, 王琪, 等.2015年中国临床实践指南的报告质量分析[J].中国循证医学杂志, 2018, 18:721-728. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201807014.htm |
[18]
|
陈耀龙, 商洪才, 杨克虎, 等.临床实践指南的国际经验和中国道路[J].协和医学杂志, 2019, 10:289-292. http://www.cnki.com.cn/Article/CJFDTotal-XHYX201903018.htm |
[19]
|
World Health Organization.WHO handbook for guideline development.Second edition[M/OL].2014. http://apps.who.int/medicinedocs/en/m/abstract/Js22083en/. |
[20]
|
Schüunemann HJ, Osborne M, Moss J, et al.An official American Thoracic Society Policy statement:managing conflict of interest in professional societies[J].Am J Respir Crit Care Med, 2009, 180:564-580. doi: 10.1164/rccm.200901-0126ST |
[21]
|
Qaseem A, Wilt TJ, Clinical Guidelines Committee of the American College of Physicians.Disclosure of interests and management of conflicts of interest in clinical guidelines and guidance statements:methods from the Clinical Guidelines Committee of the American College of Physicians[J].Ann Intern Med, 2019, 171:354-361. doi: 10.7326/M18-3279 |
[22]
|
Guyatt G, Akl EA, Hirsh J, et al.The vexing problem of guidelines and conflict of interest:a potential solution[J].Ann Intern Med, 2010, 152:738-741. doi: 10.7326/0003-4819-152-11-201006010-00254 |
[23]
|
Akl EA, El-Hachem P, Abou-Haidar H, et al.Consider-ing intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline:a descriptive study[J].J Clin Epidemiol, 2014, 67:1222-1228. doi: 10.1016/j.jclinepi.2014.05.006 |
[24]
|
Akl EA, Karl R, Guyatt GH.Methodologists and context experts disagreed regarding managing conflicts of interest of clinical practice guidelines panels[J].J Clin Epidemiol, 2012, 65:734-739. doi: 10.1016/j.jclinepi.2011.12.013 |
[25]
|
宋霄杨, 高玉婷, 周奇, 等.非经济利益冲突及其研究现状[J].中国循证医学杂志, 2017, 17:607-611. http://www.cnki.com.cn/Article/CJFDTOTAL-ZZXZ201705018.htm |
[26]
|
Bernard L, Marilyn JF.Conflict of Interest in Medical Research, Education, and Practice[M].Washington (DC):National Academies Press (US), 2009:190-210. |
[27]
|
Norris SL, Burda BU, Holmer HK, et al.Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography[J].J Clin Epidemiol, 2012, 65:725-733. doi: 10.1016/j.jclinepi.2011.12.011 |
[28]
|
Sinclair D, Isba R, Kredo T, et al.World Health Organization guideline development:an evaluation[J].PLoS One, 2013, 8:e63715. doi: 10.1371/journal.pone.0063715 |
[29]
|
Niforatos JD, Pescatore RM.Financial relationships with industry among guideline authors for the management of acute ischemic stroke[J].Am J Emerg Med, 2019, 37:921-923. doi: 10.1016/j.ajem.2019.01.037 |
[30]
|
Saito H, Ozaki A, Sawano T, et al.Evaluation of pharmaceutical company payments and conflict of interest disclo-sures among oncology clinical practice guideline authors in Japan[J].JAMA Netw Open, 2019, 2:e192834. doi: 10.1001/jamanetworkopen.2019.2834 |
[31]
|
Hart KL, Perlis RH, Perlis CS.Conflict of interest and citation impact among dermatology guideline authors[J].J Am Acad Dermatol, 2019, 80:813-815. doi: 10.1016/j.jaad.2018.10.028 |
[32]
|
Irwig MS, Kyinn M, Shefa MC.Financial conflicts of interest among authors of Endocrine Society clinical practice guidelines[J].J Clin Endocrinol Metab, 2018, 103:4333-4338. doi: 10.1210/jc.2018-00526 |
[33]
|
Carlisle A, Bowers A, Wayant C, et al.Financial conf-licts of interest among authors of urology clinical practice guidelines[J].Eur Urol, 2018, 74:348-354. doi: 10.1016/j.eururo.2018.04.023 |
[34]
|
Horn J, Checketts JX, Jawhar O, et al.Evaluation of industry relationships among authors of otolaryngology clinical practice guidelines[J].JAMA Otolaryngol Head Neck Surg, 2018, 144:194-201. doi: 10.1001/jamaoto.2017.2741 |
[35]
|
Jefferson AA, Pearson SD.Conflict of interest in seminal hepatitis C virus and cholesterol management guidelines[J].JAMA Intern Med, 2017, 177:352-357. doi: 10.1001/jamainternmed.2016.8439 |
[36]
|
王强, 黄超, 李俊, 等.2017年中国发布的临床实践指南中利益冲突与经济学证据的调查分析[J].中国循证医学杂志, 2018, 18:379-387. http://www.cnki.com.cn/Article/CJFDTotal-ZZXZ201804019.htm |
[37]
|
Brouwers MC, Kho ME, Browman GP, et al.AGREE Ⅱ:advancing guideline development, reporting and evaluation in health care[J].CMAJ, 2010, 182:E839-842. doi: 10.1503/cmaj.090449 |
[38]
|
Chen Y, Yang K, Marušic A, et al.A reporting tool for practice guidelines in health Care:The RIGHT Statement[J].Ann Intern Med, 2017, 166:128-132. doi: 10.7326/M16-1565 |
[39]
|
蒋朱明, 詹思延, 贾晓巍, 等.制订/修订《临床诊疗指南》的基本方法及程序[J].中华医学杂志, 2016, 96:250-253. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_zhyx201604007 |
[40]
|
Centers for Medicare & Medicaid Services.Open Payments[DB/OL]. https://www.cms.gov/openpayments/. |
[41]
|
肖淑君, 高玉婷, 王小琴, 等.患者指南及其制订方法介绍[J].药品评价, 2017, 14:44-48. http://www.cnki.com.cn/Article/CJFDTotal-YPPJ201706007.htm |
[42]
|
王小琴, 童雅婧, 何江华, 等.患者指南制订的基本原则和方法(一)[J].中国循证儿科杂志, 2017, 12:476-478. http://www.cnki.com.cn/Article/CJFDTotal-XZEK201706020.htm |
[43]
|
詹思延, 尹道馨, 唐金陵.中国临床指南:解决利益冲突和吸纳患者参与[J].英国医学杂志(中文版), 2019, 22:33-34. |
[44]
|
Zhan SY, Yin DX, Tang JL.Clinical guidelines in China: tackling conflict of interests and engaging patients[EB/OL].https://blogs.bmj.com/bmj/2018/11/06/clinical-guidelines-in-china-tackling-conflict-of-interests-and-engaging-patients/. |
[45]
|
王洋洋, 陈耀龙, 王小琴, 等.中医(中西医结合)临床实践指南制修订方法——利益冲突声明与管理[J].中华中医药杂志, 2016, 31:3613-3616. http://www.cnki.com.cn/Article/CJFDTotal-BXYY201609061.htm |
[46]
|
赵明娟, 靳英辉, 张菁, 等.临床实践指南制定方法——利益冲突的声明和管理[J].中国循证心血管医学杂志, 2018, 10:513-517. |
[47]
|
刘峘, 谢雁鸣, 王永炎.中医药临床实践指南制订过程中的利益冲突与声明[J].中医杂志, 2017, 58:2001-2003. http://www.cnki.com.cn/Article/CJFDTotal-ZZYZ201723006.htm |